💊
Respreeza
alpha1-proteinase inhibitor (human)
Enfermedades genéticas, congénitas; enfermedades pulmonares
✅ Autorizado
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.
⚠️ Seguridad del paciente
No
📚 Alertas pasadas (4)
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza